Skip to main content
UCB logo

UCB — Investor Relations & Filings

Ticker · UCB ISIN · BE0003739530 LEI · 2138008J191VLSGY5A09 BR Manufacturing
Open in API
Filings indexed 2,023 across all filing types
Latest filing 2011-02-10 Declaration of Voting R…
Country BE Belgium
Listing BR UCB

About UCB

https://www.ucb.com/

UCB is a global biopharmaceutical company that focuses on creating solutions for people living with severe diseases, primarily in the fields of neurology and immunology. The company's core activities include the research, development, and commercialization of pharmaceutical and biotechnology products. Guided by a patient-centric and science-driven approach, UCB is committed to innovation and sustainability. Through its UCB Ventures arm, it invests in pioneering technologies and companies with the potential to transform patient care. The company also offers personalized support services to patients and healthcare professionals during their treatment journey with a UCB medicine.

Recent filings

Filing Released Lang Actions
Transparency Wellington_ENG.pdf
Declaration of Voting Results & Voting Rights Announcements Classification · 99% confidence The document is a 'Transparency notification' from Wellington Management Company LLP dated February 10, 2011, regarding a change in their shareholding in UCB that crossed the 3% statutory threshold on February 7, 2011. This type of filing specifically reports changes in significant share ownership levels, which directly corresponds to the definition of Major Shareholding Notification (MRQ). It is not an earnings release, an annual report, or a director's dealing, but a notification about a major shareholder's stake.
2011-02-10 English
Transparency Wellington_FR.pdf
Major Shareholding Notification Classification · 98% confidence The document is a formal announcement dated February 10, 2011, detailing that Wellington Management Company LLP purchased shares in UCB, causing their holding to cross the 3% notification threshold, as required by Belgian law (loi du 2 mai 2007). This explicitly describes a change in significant share ownership by an external party. This aligns perfectly with the definition for Major Shareholding Notification (MRQ). The document is short and serves as a direct notification, not a comprehensive report.
2011-02-10 French
Transparency Wellington__NL.pdf
Declaration of Voting Results & Voting Rights Announcements Classification · 99% confidence The document is a formal announcement dated February 10, 2011, originating from Brussels, labeled as 'gereglementeerde informatie' (regulated information). The core content states that Wellington Management Company LLP acquired UCB shares, increasing their stake to 3.00%, thereby crossing a notification threshold based on a law from May 2, 2007 (likely related to major shareholdings disclosure). This directly corresponds to the definition of a Major Shareholding Notification (MRQ), which covers changes in significant share ownership levels crossing thresholds.
2011-02-10 Dutch
UCB delivers on its clinical development milestones
Earnings Release Classification · 95% confidence The document is a press release dated January 10, 2011, detailing clinical development milestones achieved by UCB during Q4 2010 (e.g., starting Phase III studies for Brivaracetam and Vimpat, initiating Phase IIb for CDP6038). This content focuses on operational and R&D progress, which is typical for an Earnings Release (ER) or a general Investor Relations announcement. Since it provides key operational highlights and financial context (revenue for 2009 is mentioned), it aligns best with the 'Earnings Release' (ER) definition, which covers initial announcements of periodical results and key highlights, even if the primary focus here is clinical pipeline updates rather than just quarterly financials. It is not a full Annual Report (10-K), a transcript (CT), or a formal Audit Report (AR). Given the nature of reporting operational achievements around a period end, ER is the most appropriate fit among the choices. Q4 2010
2011-01-10 English
UCB atteint ses objectifs en matière de développement clinique
Earnings Release Classification · 95% confidence The document is dated January 10, 2011, and is explicitly labeled as "information réglementée" (regulated information). The content details the achievement of clinical development milestones (Phase II/III launches, preliminary results) for several drug candidates (Brivaracetam, Vimpat, Epratuzumab, CDP6038) during Q4 2010. This structure—a press release announcing operational and clinical progress, often including forward-looking statements and contact information for Investor Relations—is characteristic of an Earnings Release (ER) or a general regulatory announcement. Since it focuses on operational achievements rather than comprehensive financial statements (like a 10-K or IR) or management compensation (DEF 14A), and it is an initial announcement of results/progress, the most fitting category is Earnings Release (ER). It is not a full transcript (CT), a formal annual report (10-K), or a specific capital action (CAP/SHA). Q4 2010
2011-01-10 French
UCB realiseert aangekondigde mijlpalen op vlak van klinische ontwikkeling
Regulatory Filings Classification · 96% confidence The document is a press release dated January 10, 2011, originating from UCB, detailing the achievement of several clinical development milestones (Phase III studies started, Phase II results available) for various drug candidates (Brivaracetam, Vimpat, Epratuzumab, CDP6038). It uses language typical of an 'Earnings Release' or a general corporate update announcing recent operational achievements, rather than a comprehensive financial report (10-K or IR) or a specific regulatory filing. Since it announces key operational and development highlights, the most appropriate classification among the options is 'Earnings Release' (ER), as these types of operational updates often accompany or precede formal earnings announcements, focusing on key performance indicators outside of the full financial statements. It is not a Call Transcript (CT), Investor Presentation (IP), or a formal regulatory filing like 10-K or AR. Given the content focuses on operational/development progress announced via a press release format, ER is the best fit.
2011-01-10 Dutch

Browse filings by year

18 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.